Recommendation on Pre-Methotrexate Screening
Yes, you should obtain hepatitis B, hepatitis C, and HIV serology before starting methotrexate, as recommended by international guidelines, but the mildly elevated alkaline phosphatase alone does not require further evaluation before initiating therapy given the normal transaminases and albumin. 1
Infectious Disease Screening
The multinational evidence-based recommendations explicitly state that the pre-methotrexate work-up should "consider serology for HIV, hepatitis B/C" as part of the baseline assessment 1. This is a Grade C recommendation with strong expert agreement (mean 8.2/10). The rationale is straightforward:
- Hepatitis B and C: Chronic viral hepatitis increases the risk of methotrexate-related hepatotoxicity and may alter monitoring strategies
- HIV: Immunodeficiency syndromes represent a relative contraindication to methotrexate due to increased infection risk 2
The British Association of Dermatologists guidelines similarly recommend baseline infectious screening as standard practice 3. While the evidence level is modest (Level 4), this reflects the preventive nature of screening rather than weakness of the recommendation.
Alkaline Phosphatase Elevation
The mildly elevated alkaline phosphatase (165, assuming normal range ~30-120 U/L) does not require further investigation before starting methotrexate in this clinical context because:
- AST and ALT are completely normal (12 and 13, respectively) - these are the primary hepatic monitoring parameters for methotrexate 1, 4
- Albumin is normal (4.0) - this is a key indicator of hepatic synthetic function 1
- Bilirubin is normal (0.3)
The guidelines focus monitoring on transaminases (AST/ALT), not alkaline phosphatase, for methotrexate hepatotoxicity surveillance 1, 4. Isolated alkaline phosphatase elevation often reflects bone turnover (particularly relevant in rheumatoid arthritis) or other non-hepatocellular processes.
Renal Function Consideration
The eGFR of 65 mL/min/1.73 m² represents mild renal impairment (CKD stage 2). This is clinically significant:
- Methotrexate is primarily renally excreted, and reduced clearance increases toxicity risk 5, 6
- Recent evidence suggests adverse reaction risk increases starting at CKD stage 2 6
- Start at a lower dose (consider 7.5-10 mg weekly rather than the standard 10-15 mg) 1
- Monitor more frequently - consider every 2-4 weeks initially rather than monthly 1
The absolute eosinophil count of 0.8 (assuming K/μL, which is elevated if normal range is 0.0-0.5) is a minor finding that doesn't preclude methotrexate initiation but warrants documentation for baseline comparison.
Practical Algorithm
Before prescribing methotrexate:
- ✓ Order hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody
- ✓ Order HIV serology (with appropriate patient counseling)
- ✓ Document the alkaline phosphatase elevation but proceed without further hepatic imaging or biopsy given normal transaminases and albumin
- ✓ Plan to start at reduced dose (7.5-10 mg weekly) due to eGFR 65
- ✓ Schedule laboratory monitoring (CBC, creatinine, AST/ALT, albumin) at 2-week intervals for the first 6-8 weeks
Do not delay methotrexate for alkaline phosphatase workup - the normal transaminases and albumin provide adequate reassurance of hepatic function for safe initiation.
Important Caveats
- If hepatitis B or C serology returns positive, do not automatically exclude methotrexate but adjust monitoring strategy and consider hepatology consultation 1
- The mild renal impairment substantially increases risk of methotrexate accumulation and toxicity - educate the patient about symptoms of bone marrow suppression (fever, mouth ulcers, bruising) and ensure they understand weekly (not daily) dosing 2, 7
- Ensure folic acid supplementation (at least 5 mg weekly) is prescribed concurrently 1